Our prior study also demonstrated that BRAFV600E coexisting with TERT promoter mutations contributes to adverse clinical outcomes in radioiodine-refractory differentiated thyroid cancer (49). The gene discussed is TERT; the disease is differentiated thyroid carcinoma.